Top three employer takeaways from ASCO 2026
Top three employer takeaways from ASCO 2026
Top three employer takeaways from ASCO 2026
When major breakthroughs in cancer care happen, they are often first announced at the Annual American Society of Clinical Oncology Annual Meeting (ASCO) meeting, which concluded this week. Here's what benefits leaders and HR teams should know.
Takeaway #1: Clinical breakthroughs shared for Pancreatic Cancer
It is not often that clinical trial results so dramatically improve outcomes for patients that the presentation receives a standing ovation and concurrent publication in the New England Journal of Medicine. This celebration happened on Sunday at the ASCO Plenary Session, where researchers presented results showing that daraxonrasib, a first-of-its-kind drug, nearly doubled overall survival for patients with previously treated pancreatic metastatic cancer.
Why is this breakthrough important to employers?
Pancreatic cancer is among the most feared diagnoses because typical survival rates without treatment are three to six months. While treatments have improved over the last two decades, real progress has been elusive. Now, all that has changed with daraxonrasib, a pill taken once daily.
Daraxonrasib is a new class of targeted cancer therapy designed for tumors driven by specific genetic mutations (RAS). Because the therapy is so new, most oncologists are not experienced with managing its unique side effects. Daraxonrasib is currently only available through an FDA-approved Early Access Program, which means patients also need knowledgeable oncologists to request approval and document eligibility. Breakthrough therapies increasingly depend on specialized expertise that may not be available in every care setting.
This means access to experienced cancer specialists may become increasingly important as new therapies enter practice. The difference between receiving a breakthrough therapy and benefiting from it often depends on how quickly patients reach the right specialists and receive appropriate clinical oversight.
Assuming daraxonrasib achieves full FDA approval for commercial use, it will be a “must-have” drug on formularies and insurance coverage. The market price is not yet known; I expect it will follow the high cost of other recent breakthrough cancer medications. As these therapies reach commercial markets, organizations should expect continued pressure on cancer-related pharmacy and treatment costs.
For employers, this significant advance for pancreatic cancer highlights a growing reality: breakthrough cancer therapies often bring new access and cost considerations. As more specialized treatments enter the market, making sure employees can quickly reach expert cancer specialists and receive timely coverage decisions becomes increasingly important.
Data details
The RASolute 302 trial showed that daraxonrasib increased median overall survival compared to standard chemotherapy for patients with metastatic cancer who had previously received treatment (13.2 months vs. 6.7 months). This result translates to a 60% reduction in the risk of death. (The full research paper is here)
Next steps
The outlook for employees with pancreatic cancer has greatly brightened. Employers need to take action to ensure (1) employees with pancreatic cancer can access expert medical oncologists (2) health plans and pharmacy benefit mangers cover daraxonrasib immediately after FDA approval, and (3) patients at high-risk for pancreatic cancer are identified and receive high-quality screening and active follow-up.
Takeaway #2: A new treatment paradigm for prostate cancer
A new standard of care for men with high-risk prostate cancer was also presented at the ASCO Plenary Session and concurrently published in the NEJM. By combining two different oral drugs before and after surgery, the risk of death or disease spread decreased by 20%.
Why is this breakthrough important to employers?
Prostate cancer is the most common cancer in men. Until now, there were several treatment options for patients whose prostate cancer had not spread, with similar outcomes but different side effects: surgery, radiation, or close observation. Hormonal therapy called Androgen Deprivation Therapy (ADT) was sometimes added. Many men found it hard to decide which treatment strategy to choose.
Now, men with a high-risk localized disease may have a stronger reason to consider surgery as part of their treatment plan. That decision is becoming more complex and increasingly dependent on evaluation and coordination between multiple cancer specialists (surgeons, medical oncology, and radiation oncology). This multidisciplinary expert opinion is more important than ever to ensure the men who would benefit most from this new standard of care are identified, understand the risks and benefits of different treatment options, and are treated by high-quality surgeons practicing at high-quality centers.
Data details
The PROTEUS study demonstrated that apalutamide plus ADT given for six months before and six months after surgery improved metastatic-free survival (patients are alive and without metastatic disease) at five years after treatment compared to surgery and ADT only: 78.2% versus 73.5% (HR, 0.80; 95% CI, 0.67-0.96; p = 0.02).
Importantly, patients on the combination therapy were nine times more likely to have little to no cancer remaining in the prostate when removed surgically: 8.9% versus 1.0% (odds ratio, 10.17; P < .0001). Research evaluating this combination compared to radiation plus ADT, which is a commonly used standard of care, is ongoing. (The research abstract is here and summary by ASCO is here)
Next steps
This new standard of care increases the importance of making sure men with high-risk prostate cancer are evaluated by the right specialists before treatment decisions are made. Employers need to take action to ensure (1) patients can access multidisciplinary cancer specialists who understand the latest evidence, (2) patients receive clear information about the risks and benefits of surgery, radiation, and systemic therapy, and (3) patients can access high-quality treatment centers and surgeons when appropriate. As treatment options become more personalized, expert review is increasingly important to ensure patients receive the treatment strategy most likely to improve outcomes.
Takeaway #3: Encouraging preliminary GLP-1 data shared for cancer prevention
A new, very large observational study suggests GLP-1 drugs such as semaglutide and tirzepatide may improve outcomes for patients with cancer. While the results need validation in prospective randomized trials, these findings open new potential avenues for the treatment of cancer.
Why are these results important to employers?
These findings reinforce the growing connection between chronic disease management and cancer outcomes. Benefit decisions related to obesity, diabetes, and metabolic health may increasingly influence cancer outcomes and costs as well, making the assessment of the downstream value more complex.
Data details
Analysis of 12,000 patients with one of seven cancer types that had not spread, found that those who started taking a GLP-1 after diagnosis were 38–50% less likely to progress (e.g. develop metastatic cancer) than those who started a diabetes medication from a different drug class (DPP-4 inhibitor such as Sitagliptin), regardless of weight and a number of other factors. In addition, patients taking GLP-1s were 33% less likely to die. (Research abstract is here and a summary by ASCO is here)
Next steps
It is too early to start GLP-1 treatment as a proven method to reduce cancer risk. However, these early signals mean organizations need to develop a comprehensive cancer strategy now. Employers covering GLP-1 drugs may eventually be able to consider cancer-related benefits alongside their impact on weight management, diabetes, and other metabolic conditions. However, the evidence is still early, and coverage decisions should continue to be based on established clinical guidelines.
The Bottom Line
ASCO 2026 reinforced a trend we've seen building for years: the boundary between cancer advances and employer benefits strategy is collapsing.
Whether it's GLP-1 coverage, ensuring access to breakthrough therapies, or investing in workforce wellbeing and cancer screening, the decisions employers make today directly shape cancer outcomes and costs for years to come.
Across all three ASCO presentations, the pace of change in cancer care was clear. New therapies are entering practice, treatment decisions are becoming more individualized, and the number of cancer survivors continues to grow. Together, these trends increase the importance of timely access to expert cancer care across the entire cancer journey.
As the first virtual practice to receive ASCO Certification, Color's Virtual Cancer Clinic is built for these challenges, from screening through active treatment and into survivorship, delivering access, speed, and direct clinical care when it matters most.